Industry news that matters to you.  Learn more

Archives for March 2016

ImmunID Signs Master Collaboration Agreement with MSK About the Prediction of Response to Immuno-Oncology Agents Using ImmunTraCkeR

ImmunID, the immune companion diagnostics for precision medicine company, recently announced that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world’s oldest and largest private cancer center. It has ranked as one of the top two hospitals for cancer care in the United States for more than 25 years.

Collaboration Led by ImmunID Awarded Innovate UK Grant to Advance Program on Prediction of Response to Cancer Immunotherapy Using ImmunTraCkeR

ImmunID, the immune companion diagnostics for precision medicine company, recently announced it has been awarded Small Business Research Initiative funding1 by Innovate UK, UK’s innovation agency, to advance its ImmunTraCkeR® assay for therapeutic response prediction. The project aims at validating ImmunID’s clinical results with ImmunTraCkeR® through a clinical study on 40 metastatic melanoma patients from the UK, treated with immunotherapy. It also includes a medico-economic study to measure the health economic benefits for the National Health Service (NHS), the UK healthcare system. The National Institute for Health Research Diagnostic Evidence Co-operative Leeds (NIHR DEC Leeds) and the Precision Medicine Catapult are collaborating on the project. The Catapult’s Centres of Excellence in Leeds and Glasgow will provide health-informatic and data-analytic support to mine local and national health records, providing real world NHS data for the economic modelling. Ultimately, ImmunTraCkeR® may be used as an immune companion diagnostic to immune checkpoint agents and help doctors make informed decisions regarding the treatment of melanoma, therefore improving patient benefit whilst saving unnecessary healthcare costs.

New Nanotechnology Detects Biomarkers of Cancer

Researchers at Wake Forest Baptist Medical Center have developed a new technology to detect disease biomarkers in the form of nucleic acids, the building blocks of all living organisms.

Thermo Fisher Scientific Announces Expanded FDA Clearance for its B·R·A·H·M·S PCT Sepsis Biomarker

Thermo Fisher Scientific Inc., the world leader in serving science, recently announced it has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (procalcitonin) biomarker assay for sepsis risk assessment. PCT is a sensitive and specific biomarker of systemic bacterial infection. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four. The change in PCT over time, in conjunction with other laboratory findings and clinical assessments aids in assessing the cumulative 28-day risk of mortality for patients with severe sepsis or septic shock who are admitted to the intensive care unit.

New Pilot Study Finds Cosamin ASU Effective in Reducing Concentrations of Key Biomarkers Associated with Joint Discomfort and Cartilage Breakdown

Nutramax Laboratories Consumer Care, Inc. recently announced the results of a six-week, open-label pilot study that found Cosamin®ASU, the company’s advanced joint health formulation, is effective in reducing concentrations of serum and urine biomarkers associated with joint discomfort and cartilage breakdown. The study, carried out by researchers at the University of Missouri, also included clinical assessments which found that Cosamin ASU may be associated with improvements in measures of function and quality of life.